New methods to the patient management with irritable bowel syndrome
DOI: DOI: 10.32364/2587-6821-2021-5-6-391-397
M.A. Livzan, O.V. Gaus
Omsk State Medical University, Omsk, Russian Federation
Aim: to evaluate the efficacy and safety of Kolofort® in the treatment of patients with moderate to mild irritable bowel syndrome (IBS).
Patients and Methods: an open cohort prospective placebo-controlled study was conducted with the inclusion of 30 patients (average age 30.7±7.8 years) with an established diagnosis of IBS. The control group consisted of 10 healthy subjects. Kolofort® was prescribed for a course of 12 weeks, 2 tablets 2 times a day. All patients were evaluated before and after the therapy course for the main clinical symptoms of IBS, as well as the severity of anxiety and depression, the level of specific anxiety regarding GIT symptoms and life quality. Cortisol levels in the morning and evening portions of saliva were determined in healthy subjects and patients with IBS.
Results: initially, patients with IBS had a high level of anxiety and depression, a high index of visceral hyperssensitivity, and a low life quality. In patients with IBS, the cortisol level in the morning and evening portions of saliva before treatment was statistically significantly higher than in healthy subjects (in both cases, p<0,05). After 12 weeks of therapy, there was a statistically significant decrease in the severity of clinical manifestations of the disease (p<0,05), in the severity of depression, anxiety, visceral hypersensitivity and an increase in the life quality. After the therapy course, patients with IBS noted a significant decrease in the cortisol level in the morning and evening portions of saliva. During therapy, 3 adverse events were registered: headache (n=2), nausea (n=1), which did not require drug discontinuation.
Conclusion: the efficacy of Kolofort® in the treatment of patients with IBS with a moderate and mild disease course, both in relation to the main GIT symptoms and concomitant psychoemotional disorders, has been shown. Good efficacy and tolerability of the drug ensured high patient adherence to the treatment.
Keywords: irritable bowel syndrome, cortisol, stress, Kolofort, visceral hyperssensitivity, anxiety.
For citation: Livzan M.A., Gaus O.V. New methods to the patient management with irritable bowel syndrome. Russian Medical Inquiry. 2021;5(6):391–397 (in Russ.). DOI: 10.32364/2587-6821-2021-5-6-391-397.
Aknowledgement
The technical edition is supported by to NPF MATERIA MEDICA HOLDING LLC.
About the authors:
Maria A. Livzan — Dr. Sc. (Med.), Professor, Head of the Department of Faculty Therapy and Gastroenterology, Rector, Omsk State Medical University; 12, Lenina str., Omsk, 644099, Russian Federation; ORCID iD 0000-0002-6581-7017.
Olga V. Gaus — C. Sc. (Med.), Associate Professor of the Department of Faculty Therapy and Gastroenterology, Head of the Department for the Development of Regional Healthcare and Medical Activities, Omsk State Medical University; 12, Lenina str., Omsk, 644099, Russian Federation; ORCID iD 0000-0001-9370-4768.
Contact information: Olga V. Gaus, e-mail: gaus_olga@bk.ru
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 12.07.2021.
Revised 04.08.2021.
Accepted 27.08.2021.
2. Gaus O.V., Livzan M.A. IBS: What Do We Know About Symptoms Today? Consilium Medicum. 2019;21(8):42–48 (in Russ.). DOI: 10.26442 / 20751753.2019.8.190512.
3. Malagelada J.R., Malagelada C. Mechanism-Oriented Therapy of Irritable Bowel Syndrome. Adv Ther. 2016;33:877–893. DOI: 10.1007/s12325-016-0336-3.
4. Schmulson M.J., Drossman D.A. What Is New in Rome IV. J Neurogastroenterol Motil. 2017;23(2):151–163. DOI: 10.5056/jnm16214.
5. Clinical guidelines of the Ministry of Health of the Russian Federation. Irritable Bowel Syndrome. (Electronic resource.) (in Russ.). URL: https://cr.minzdrav.gov.ru/schema/190_2 (access date: 07.25.2021).
6. Ivashkin V.T., Shelygin Yu.A., Baranskaya E.K. and other Clinical guidelines of the Russian Gastroenterological Association and the Association of Coloproctologists of Russia for the diagnosis and treatment of irritable bowel syndrome. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii. 2017;27(5):76–93 (in Russ.).
7. Farmer A.D., Wood E., Ruffle J.K. An approach to the care of patients with irritable bowel syndrome. CMAJ. 2020;192:E275–282. DOI: 10.1503/cmaj.190716.
8. Akhmedov V.A., Orlov I.N., Gaus O.V. Modern methods of rehabilitation of patients with irritable bowel syndrome. Terapiya. 2017;3(13) 49–55 (in Russ.).
9. Chang L., Sundaresh S., Elliott J. et al. Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis in irritable bowel syndrome. Neurogastroenterol Motil. 2009;21:149–159. DOI: 10.1111/j.1365-2982.2008.01171.x.
10. Eriksson E.M., Andren K.I., Eriksson H.T., Kurlberg G.K. Irritable bowel syndrome subtypes differ in body awareness, psychological symptoms and biochemical stress markers. World J Gastroenterol. 2008;14:4889–4896. DOI: 10.3748/wjg.14.4889.
11. Sugaya N., Izawa S., Saito K. et al. Effect of prolonged stress on the adrenal hormones of individuals with irritable bowel syndrome. BioPsychoSocial Medicine. 2015;9:4. DOI: 10.1186/s13030-015-0031-7.
12. Kolofort instructions for use of the drug. (Electronic resource.) URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=58b244a0-60a5-4a1e-8e0a-cdc7edf6b06aandt= (access date: 07.25.2021) (in Russ.).
13. Khakimova G.R., Dugina Yu.L., Ertuzun I.A., Epshtein O.I. Anti-inflammatory, analgesic and immunomodulatory activity of RA anti-TNF-α-active substance of the drugs Artrfoon and Kolofort. Patogenez. 2016;14(4):22–29 (in Russ.).
14. Avalueva E.B., Adasheva T.V., Babaeva A.R. et al. Efficacy and safety of Kolofort in irritable bowel syndrome: results of a multicenter, double-blind, placebo-controlled, randomized clinical trial. Gastroenterology. 2014;1:36–43 (in Russ.).
15. Maev I.V., Samsonov A.A., Yashina A.V. et al. Clinical efficacy and safety of treatment regimens for irritable bowel syndrome (results of a comparative study). Consilium Medicum. 2016;18(8):19–26 (in Russ.).
16. Ivashkin V.T., Poluektova E.A., Glazunov A.B. et al. Pathogenetic approach to the treatment of functional disorders of the gastrointestinal tract and their intersection: results of the Russian observation retrospective program COMFORT. BMC. Gastroenterology. 2020;20:2. DOI: 10.21203/rs.2.13285/v2.
17. Labus J.S., Mayer E.A., Chang L. et al. The Central Role of Gastrointestinal-Specific Anxiety in Irritable Bowel Syndrome: Further Validation of the Visceral Sensitivity Index. Psychosom Med. 2007;69(1):89–98. DOI: 10.1097/PSY.0b013e31802e2f24.
18. Mnatsakanyan M.G., Pogromov A.P., Tashchyan O.V., Kolosova K.Yu. Visceral sensitivity index in IBS patients of different ages. Eksperimental’naya i klinicheskaya gastroenterologiya. 2020;174(2):65–70 (in Russ.).
19. Drossman D.A., Patrick D.L., Whitehead W.E. et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol. 2000;95:999–1007. DOI: 10.1111/j.1572-0241.2000.01941.x.
20. Lee С., Doo E., Choi J.M. et al. The Increased Level of Depression and Anxiety in Irritable Bowel Syndrome Patients Compared with Healthy Controls: Systematic Review and Meta-analysis. J Neurogastroenterol Motil. 2017;23(3):349–362. DOI: 10.5056/jnm16220.
21. Morozova M.A., Rupchev G.E., Alekseev A.A. et al. Dysphoric spectrum of emotional disorders in patients with irritable bowel syndrome. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii. 2017;27(1):12–22 (in Russ.).
22. Midenfjord I., Borg A., Törnblom H., Simrén M. Cumulative effect of psychological alterations on gastrointestinal symptom severity in irritable bowel syndrome. Am J Gastroenterol. 2021;116(4):769–779. DOI: 10.14309/ajg.0000000000001038.
23. Livzan M.A., Gaus O.V., Turchaninov D.V., Popello D.V. Abdominal pain syndrome among youth: prevalence and risk factors. Eksperimental’naya i klinicheskaya gastroenterologiya. 2019;170(10):12–17 (in Russ.).
24. Chrousos G.P. Stress, chronic inflammation, and emotional and physical well-being: concurrent effects and chronic sequelae. J Allergy Clin Immunol. 2000;106:S275–291. DOI: 0.1067/mai.2000.110163.
25. Elenkov U., Chrousos G.P. Stress hormones, Th1/Th2 patterns, pro/anti-inflammatory cytokines and susceptibility to disease. Trends Endocrinol Metab. 1999;10:359–368. DOI: 10.1016/S1043-2760(99)00188-5.
26. Barbara G., Wang B., Stanghellini V. et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology. 2007;132:26–37. DOI: 10.1016/S1043-2760(99)00188-5. 10.1053/j.gastro.2006.11.039.
27. Buhner S., Li Q., Vignali S. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology. 2009;137:1425–1234. DOI: 10.1053/j.gastro.2009.07.005.
28. Fukudo S. Stress and visceral pain: Focusing on irritable bowel syndrome. Pain. 2013;154:S63–70. DOI: 10.1016/j.pain.2013.09.008.
29. Drossman D., Morris C.B., Hu Y. et al. Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment. Am J Gastroenterol. 2007;11:1442–1453. DOI: 10.1111/j.1572-0241.2007.01283.x.
30. Nikolaev N.A., Martynov A.I., Skirdenko Yu.P. et al. Treatment management based on adherence. Consilium Мedicum. 2020;22(5):9–18 (in Russ.).
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать